Enterome's CD candidate well tolerated in Phase I

Enterome Bioscience S.A. (Paris, France) reported data from a Phase I trial in about 60 healthy volunteers showing that single and multiple ascending oral doses of Crohn's disease candidate EB8018 (EP8018) were well tolerated.

The double-blind, placebo-controlled, U.K. trial's primary endpoint is safety. Secondary endpoints include pharmacokinetics and microbiome richness...